The recombinant protein COVID-19 vaccine developed by a key laboratory of biological therapy of West China Hospital of Sichuan University was approved by the State Drug Administration for clinical trials, according to Jiemian.com.
This is China's first recombinant protein COVID-19 vaccine produced from insect cells.
The vaccine targets the spike protein receptor binding domain (S-RBD) of SARS-CoV-2 and produces neutralizing antibodies to block the virus from infecting human cells.
The vaccine was tested on monkeys and other animals, and it was found to have a good protective effect against SARS-CoV-2 infection, and no obvious side effects were seen.
In April this year, the vaccine research team, West China Hospital of Sichuan University, and Chengdu Tianfu International Bio-town established Chengdu Weisike Bio-Pharmaceutical, which is planning and designing a production line with an annual output of hundreds of millions of needle injections. A complete set of domestic equipment will be developed independently too.
Chengdu Tianfu International Bio-town was jointly built by Chengdu High-tech Zone and Shuangliu District, with a planned area of approximately 44 square kilometers.
The vaccine industrialization project located in Chengdu Tianfu International Bio-town covers an area of 6000 square meters. It is currently undergoing workshop design, equipment selection and environmental assessment work. The plant is expected to be put into use by the end of the year.